Home / CLRB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CLRB make money? Does CLRB have pricing power? What's the Earnings Whisper? Will CLRB profit more as the business scales? What is CLRB's management track record? Is CLRB's current price justified?

Cellectar Biosciences, Inc.

$2.31 -$1.16 (-33.43%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$2.37

Day Range

$2.31$2.38

Year Range

$2.2$6.52

Market Cap

18.46M

AVG Volume

1.07M

Trailing/Forward PE

-0.51/-

PEG ratio

0.02

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD)

CLRB Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-6.93M
26 Q1	-5.65M
25 Q4	-5.3M
25 Q3	-4.44M
25 Q2	-5.45M
25 Q1	-6.6M
24 Q4	-2.36M
24 Q3	-14.66M
24 Q2	-919.37K
24 Q1	-26.64M

Operating Income (USD)

CLRB Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-7.2M
26 Q1	-5.79M
25 Q4	-5.69M
25 Q3	-4.85M
25 Q2	-6.04M
25 Q1	-6.4M
24 Q4	-12.74M
24 Q3	-13.33M
24 Q2	-13.7M
24 Q1	-12M

EBITDA (USD)

CLRB EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-6.93M
26 Q1	-5.76M
25 Q4	-5.25M
25 Q3	-4.39M
25 Q2	-5.39M
25 Q1	-6.55M
24 Q4	-2.22M
24 Q3	-14.6M
24 Q2	-853.35K
24 Q1	-26.55M

Cash Flows (USD)

CLRB Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-6.01M
26 Q1	-4.85M
25 Q4	-4.35M
25 Q3	-4.28M
25 Q2	-5.12M
25 Q1	-9.38M
24 Q4	-10.97M
24 Q3	-9.17M
24 Q2	-14.16M
24 Q1	-13.38M

EPS (USD)

CLRB EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.57
26 Q1	-1.33
25 Q4	-1.25
25 Q3	-1.41
25 Q2	-3.39
25 Q1	-4.3
24 Q4	-1.68
24 Q3	-11.18
24 Q2	-5.43
24 Q1	-27.24

Expenses (USD)

CLRB Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	7.2M
26 Q1	5.91M
25 Q4	5.7M
25 Q3	4.85M
25 Q2	6.04M
25 Q1	6.4M
24 Q4	12.81M
24 Q3	13.33M
24 Q2	13.72M
24 Q1	12.02M

Cash & Debt (USD)

CLRB Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	33.99M
26 Q1	8.35M
25 Q4	13.2M
25 Q3	12.55M
25 Q2	11.04M
25 Q1	13.91M
24 Q4	23.29M
24 Q3	34.26M
24 Q2	25.87M
24 Q1	40.03M

Debt ratios

CLRB Debt ratios by quarter
Period	Debt ratios
26 Q2	1.45
26 Q1	0.33
25 Q4	0.59
25 Q3	0.65
25 Q2	0.37
25 Q1	0.55
24 Q4	0.52
24 Q3	0.68
24 Q2	0.48
24 Q1	0.64

Return on Capital

CLRB Return on Capital by quarter
Period	Return on Capital
26 Q2	-23.2%
26 Q1	-119.86%
25 Q4	-53.38%
25 Q3	-47.38%
25 Q2	-72.96%
25 Q1	-80.02%
24 Q4	-16.48%
24 Q3	-96.7%
24 Q2	-6.68%
24 Q1	-191.9%

Shares Outstanding

CLRB Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	12.23M
26 Q1	4.24M
25 Q4	4.24M
25 Q3	3.16M
25 Q2	1.61M
25 Q1	1.54M
24 Q4	1.4M
24 Q3	1.31M
24 Q2	169K
24 Q1	978.22K

Book Value Per Share (USD)

CLRB Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	2.44
26 Q1	1.11
25 Q4	2.34
25 Q3	2.97
25 Q2	4.64
25 Q1	5.37
24 Q4	10.23
24 Q3	11.57
24 Q2	81.44
24 Q1	14.19

Total Assets (USD)

CLRB Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	36.64M
26 Q1	11.12M
25 Q4	14.98M
25 Q3	14.63M
25 Q2	13.7M
25 Q1	16.04M
24 Q4	25.47M
24 Q3	37.29M
24 Q2	29.38M
24 Q1	42.91M

Employee Count

CLRB Employee Count by quarter
Period	Employee Count
2025	11
2024	11
2023	20
2022	15
2021	12
2020	11
2019	8
2018	7
2017	15
2016	15

Free Cash Flow Yield

CLRB Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-68.96%
Sep 26	-67.21%
Aug 26	-62.96%
Aug 26	-61.5%
Aug 26	-61.27%
Aug 26	-170.59%
Jul 26	-170.59%
Jul 26	-181.92%
Jul 26	-174.67%
Jul 26	-155.47%
Jul 26	-156.02%
Jun 26	-173.98%
Jun 26	-157.14%
Jun 26	-196.6%
Jun 26	-169.27%
May 26	-139.62%
May 26	-137.01%
May 26	-141.88%
May 26	-175.92%
May 26	-202.74%
Apr 26	-197.6%
Apr 26	-186.77%
Apr 26	-197.6%
Apr 26	-213.87%
Mar 26	-201.99%
Mar 26	-168.32%
Mar 26	-170.43%
Mar 26	-197.6%
Feb 26	-289.48%
Feb 26	-278.35%
Feb 26	-285.96%
Feb 26	-309.48%
Jan 26	-292.18%
Jan 26	-248.24%
Jan 26	-262.06%
Jan 26	-305.46%
Jan 26	-271.13%
Dec 25	-367.5%
Dec 25	-351.05%
Dec 25	-259.89%
Dec 25	-249.55%
Nov 25	-262.06%
Nov 25	-328.96%
Nov 25	-324.42%
Nov 25	-635.16%
Oct 25	-635.16%
Oct 25	-538.3%
Oct 25	-478.49%
Oct 25	-464.05%
Oct 25	-372.53%
Sep 25	-390.07%
Sep 25	-414.08%
Sep 25	-423.86%
Sep 25	-432.37%
Aug 25	-442.13%
Aug 25	-441.23%
Aug 25	-496.13%
Aug 25	-601.32%
Aug 25	-602.59%
Jul 25	-558.79%
Jul 25	-569.99%
Jul 25	-582.84%
Jul 25	-592.55%
Jun 25	-360.03%
Jun 25	-325.06%
Jun 25	-229.37%
Jun 25	-262.87%
May 25	-371.8%
May 25	-380.75%
May 25	-386.97%
May 25	-460.05%
May 25	-420.39%
Apr 25	-367.05%
Apr 25	-380.55%
Apr 25	-407.34%
Apr 25	-430.46%
Mar 25	-339.99%
Mar 25	-308.36%
Mar 25	-360.46%
Mar 25	-372.34%
Feb 25	-409.23%
Feb 25	-380.31%
Feb 25	-407.35%
Feb 25	-394.68%
Jan 25	-471.1%
Jan 25	-457.74%
Jan 25	-485.92%
Jan 25	-419.37%
Jan 25	-342.87%
Dec 24	-383.6%
Dec 24	-503.84%
Dec 24	-455.4%
Dec 24	-85.18%
Nov 24	-76.89%
Nov 24	-74.94%
Nov 24	-488.57%
Nov 24	-428.65%
Nov 24	-447.66%
Oct 24	-66.2%
Oct 24	-64.3%

Price to Book

CLRB Price to Book by quarter
Period	Price to Book
Sep 26	0.95
Sep 26	0.97
Aug 26	1.04
Aug 26	1.06
Aug 26	1.06
Aug 26	2.31
Jul 26	2.31
Jul 26	2.17
Jul 26	2.26
Jul 26	2.53
Jul 26	2.53
Jun 26	2.27
Jun 26	2.51
Jun 26	2
Jun 26	2.33
May 26	2.82
May 26	2.88
May 26	2.78
May 26	1.33
May 26	1.15
Apr 26	1.18
Apr 26	1.25
Apr 26	1.18
Apr 26	1.09
Mar 26	1.15
Mar 26	1.38
Mar 26	1.37
Mar 26	1.18
Feb 26	1.1
Feb 26	1.14
Feb 26	1.11
Feb 26	1.02
Jan 26	1.09
Jan 26	1.28
Jan 26	1.21
Jan 26	1.04
Jan 26	1.17
Dec 25	0.86
Dec 25	0.9
Dec 25	1.22
Dec 25	1.27
Nov 25	1.21
Nov 25	0.96
Nov 25	0.98
Nov 25	0.73
Oct 25	0.73
Oct 25	0.86
Oct 25	0.97
Oct 25	1
Oct 25	1.25
Sep 25	1.19
Sep 25	1.12
Sep 25	1.09
Sep 25	1.07
Aug 25	1.05
Aug 25	1.05
Aug 25	0.94
Aug 25	0.88
Aug 25	0.88
Jul 25	0.95
Jul 25	0.93
Jul 25	0.91
Jul 25	0.89
Jun 25	1.47
Jun 25	1.63
Jun 25	2.31
Jun 25	2.01
May 25	1.42
May 25	1.39
May 25	1.37
May 25	0.73
May 25	0.79
Apr 25	0.91
Apr 25	0.88
Apr 25	0.82
Apr 25	0.77
Mar 25	0.98
Mar 25	1.08
Mar 25	0.93
Mar 25	0.82
Feb 25	0.75
Feb 25	0.81
Feb 25	0.75
Feb 25	0.78
Jan 25	0.65
Jan 25	0.67
Jan 25	0.63
Jan 25	0.73
Jan 25	0.9
Dec 24	0.8
Dec 24	0.61
Dec 24	0.67
Dec 24	3.61
Nov 24	3.99
Nov 24	4.1
Nov 24	0.69
Nov 24	0.78
Nov 24	0.75
Oct 24	4.29
Oct 24	4.42

No video analysis for this stock yet. Request one from our team.

News: CLRB

seekingalpha.com · 18 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript

seekingalpha.com · 13 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

globenewswire.com · 13 Aug 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

defenseworld.net · 11 Aug 2026

Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00

Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on

globenewswire.com · 30 Jul 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m.

globenewswire.com · 15 Jul 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma